REG - Futura Medical PLC - Futura Receives Approval from EU Notified Body

Futura MedicalAnnouncement

30/04/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210430:nRSd1431Xa&default-theme=true

RNS Number : 1431X  Futura Medical PLC  30 April 2021

 

30 April 2021

Futura Medical Receives Approval from EU Notified Body for MED3000

Breakthrough, fast acting topical gel formulation MED3000 becomes Europe's
first approved clinically proven, topical treatment for erectile dysfunction
available without the need of a doctor's prescription

 

Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), a pharmaceutical
company developing a portfolio of innovative products based on its
proprietary, transdermal DermaSys® drug delivery technology and currently
focused on sexual health and pain, today announces that further to the
announcement of 19 March 2021, the Company has now received its MDR EU Quality
Management Certificate for the placing on the market of a Class II(b) medical
device known as MED3000 ("CE mark approval").

 

Futura's breakthrough, fast acting topical gel formulation MED3000, is the
first clinically proven, pan-European topical treatment for adult men with
erectile dysfunction ("ED") available without a doctor's prescription ("OTC").

 

Studies have shown MED3000 to be an extremely effective treatment for ED with
an excellent safety profile. MED3000 has a unique evaporative mode of action
which the Company believes stimulates nerve endings in the glans penis to
cause an erection.  MED3000 helps men get an erection within 10 minutes,
substantially faster than oral tablet phosphodiesterase-5 inhibitors
(PDE5i's), with significant benefits for spontaneous rather than pre-planned
sexual intercourse.

 

The CE mark approval of MED3000 from the EU Notified Body paves the way for
approval in many countries around the world, including in the Middle East,
Africa, the Far East and Latin American regions which allow "fast-track"
review based on recognition of the EU CE mark. Due to post-Brexit
arrangements, the EU CE mark can be used to market the product in Great
Britain until 30 June 2023 by which time a specific UKCA mark has to be
obtained. This will be a streamlined process since it is understood the UK
application can bridge to the EU approval.

 

Manufacturing scale up and commercial discussions continue to progress well
and the Company looks forward to updating shareholders further in the coming
months.

 

The prevalence of ED disrupts the lives of at least 1 in 5 men globally, with
around 23 million men in the US and 20 million men in the UK, France, Italy
and Germany. There has been little innovation in ED treatments for over ten
years and many patients continue to suffer dissatisfaction with existing
treatments.

 

James Barder, Chief Executive of Futura Medical commented: "Today marks a
transformational milestone for the Company. We are excited to be able to offer
MED3000 to millions of patients in Europe as the first, clinically proven OTC
treatment for erectile dysfunction. MED3000 is a highly differentiated
product, with a rapid speed of onset addressing significant unmet needs,
across all patient severities in the $5.6 billion global ED market.  We look
forward to further MED3000 marketing approvals in the coming years in multiple
regions across the world, including the USA and Asia."

 

Professor David Ralph, Consultant Urologist at University College London and
past president of the European Society of Sexual Medicine commented on the
approval: "The efficacy of MED3000 is remarkable and approaches the efficacy
of current first line therapy but with significantly lower adverse events.
With topical application, it will be of particular appeal to patients who want
a fast onset of action. Lack of drug interactions with prescription products
will enable the product to be used with other medications such as nitrates and
other cardiovascular drugs. It can also potentially be used in conjunction
with other ED products to improve overall efficacy to patients. As such the
product will be of great interest to the medical community."

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulation
(EU) No. 596/2014 as amended by The Market Abuse (Amendment) (EU Exit)
Regulations 2019. Upon the publication of this announcement via the Regulatory
Information Service, this inside information is now considered to be in the
public domain.

 

 

-ENDS-

 

For further information please contact:

 

Futura Medical plc

James Barder, Chief Executive

Angela Hildreth, Finance Director and COO

Email: investor.relations@futuramedical.com

Tel: +44 (0) 1483 685 670

www.futuramedical.com

 

Nominated Adviser and Sole Broker:

 

Liberum

Richard Lindley/ Euan Brown/ Kane Collings

Tel: +44 (0) 20 3100 2000

 

For media enquiries please contact:

 

Optimum Strategic Communications

Mary Clark/ Eva Haas/ Hollie Vile

Email: futuramedical@optimumcomms.com

Tel: +44 (0) 203 922 0891

 

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a
portfolio of innovative products based on its proprietary, transdermal
DermaSys® technology. Each DermaSys® formulation is separately patented and
specifically tailored for the selected indication and application, as well as
being optimised for clinical efficacy, safety, administration and patient
convenience. The products are developed for the prescription and consumer
healthcare markets as appropriate. Current therapeutic areas are sexual
health, including erectile dysfunction, and pain relief. Development and
commercialisation strategies are designed to maximise product differentiation
and value creation whilst minimising risk.

MED3000 is Futura's topical gel formulation that is a breakthrough treatment
for erectile dysfunction (ED) through a unique evaporative mode of action.
Futura has conducted a Phase 3 study using MED3000 in ED, referred to as
"FM57". This was a 1,000 patient, dose-ranging, multi-centre, randomised,
double blind, placebo-controlled, home use, parallel group study delivering
highly statistically significant results compared to pre-treatment baseline,
consistently meeting all co-primary endpoints of IIEF, SEP2 and SEP3
(internationally accepted clinical trial endpoints in ED) with over 60% of
patients experiencing a clinically meaningful improvement in their ED.
MED3000 also begins to work immediately in some patients, with 60% of patients
seeing onset of their erection within 10 minutes of application. MED3000 is CE
marked in Europe and the UK as a clinical proven topical treatment for adult
men with erectile dysfunction.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market
of the London Stock Exchange. www.futuramedical.com
(https://www.futuramedical.com/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  REAVKLFLFZLBBBZ